TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Placebo Controlled Study Evaluating the Efficacy of Aerosal® in the Treatment of Sub-Obstructive Adenotonsillar Hypertrophy and Related Diseases
Brief Summary: The purpose of this study is to evaluate the efficacy of Aerosal® compared to a placebo treatment in the prognosis of sub-obstructive adenotonsillar hypertrophy present for at least six months.


Options:
A: Arm Label: Early AT Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy (AT) - removal of adenoids and tonsils | Arm Label: Watchful Waiting; Type: OTHER; Interventions: Other: Watchful Waiting | Intervention Type: PROCEDURE; Name: Adenotonsillectomy (AT) - removal of adenoids and tonsils; Assigned to Arm(s): Early AT Surgery | Intervention Type: OTHER; Name: Watchful Waiting; Assigned to Arm(s): Watchful Waiting
B: Arm Label: Aerosal; Type: EXPERIMENTAL; Interventions: Device: Halotherapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Intervention Type: DEVICE; Name: Halotherapy; Assigned to Arm(s): Aerosal | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity of the Human Rotavirus Vaccine (Rotarix™) at Varying Schedules, Doses, and Ages in Rural Ghana
Brief Summary: The purpose of this study is to determine whether giving the Human Rotavirus Vaccine on alternate dosing schedules will enhance the immune response to the vaccine in a low-resource, high-burden country in Africa. Alternate dosing schedules studied include giving the 2-dose vaccine schedule at a slightly older age and giving an additional dose of the vaccine.


Options:
A: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
B: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks
C: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Primary 1: Rotavirus vaccine 6 and 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 6, 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine withholding breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine with immediate breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Baseline seroconversion for rotavirus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine; Assigned to Arm(s): Primary 1: Rotavirus vaccine 10 and 14 weeks, Primary 1: Rotavirus vaccine 6 and 10 weeks, Primary 1: Rotavirus vaccine 6, 10 and 14 weeks, Primary 2: Rotavirus vaccine with immediate breast feeding, Primary 2: Rotavirus vaccine withholding breast feeding

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity of the Human Rotavirus Vaccine (Rotarix™) at Varying Schedules, Doses, and Ages in Rural Ghana
Brief Summary: The purpose of this study is to determine whether giving the Human Rotavirus Vaccine on alternate dosing schedules will enhance the immune response to the vaccine in a low-resource, high-burden country in Africa. Alternate dosing schedules studied include giving the 2-dose vaccine schedule at a slightly older age and giving an additional dose of the vaccine.


Options:
A: Arm Label: Rotavirus Vaccine at age 6 & 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 10 & 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Arm Label: Rotavirus vaccine at age 6,10,&14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Human Rotavirus Vaccine | Intervention Type: BIOLOGICAL; Name: Human Rotavirus Vaccine; Assigned to Arm(s): Rotavirus Vaccine at age 6 & 10 weeks, Rotavirus vaccine at age 10 & 14 weeks, Rotavirus vaccine at age 6,10,&14 weeks
B: Intervention Type: BIOLOGICAL; Name: Rotavirus; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
D: Arm Label: V260 with staggered EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with staggered EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Arm Label: V260 with concomitant EPI; Type: EXPERIMENTAL; Interventions: Biological: V260, Biological: OPV, Biological: DTaP | Arm Label: Placebo with concomitant EPI; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo to V260, Biological: OPV, Biological: DTaP | Intervention Type: BIOLOGICAL; Name: V260; Assigned to Arm(s): V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: Placebo to V260; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI | Intervention Type: BIOLOGICAL; Name: DTaP; Assigned to Arm(s): Placebo with concomitant EPI, Placebo with staggered EPI, V260 with concomitant EPI, V260 with staggered EPI

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal High-flow Oxygen Therapy vs Standard Oxygen Therapy Via Venturi Mask in the Post-extubation Period
Brief Summary: The aim of the study is to compare two devices for oxygen therapy, nasal high-flow and Venturi mask, in critically ill patients in the post-extubation period. The hypothesis is that nasal high-flow may be superior to the Venturi mask in terms of oxygenation


Options:
A: Arm Label: Venturi group; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask, Drug: Oxygen | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: High Flow Nasal Canula (HFNC), Drug: Oxygen | Intervention Type: DEVICE; Name: High Flow Nasal Canula (HFNC); Assigned to Arm(s): HFNC group | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi group | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): HFNC group, Venturi group
B: Arm Label: Optiflow then CPAP; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Arm Label: CPAP then Optiflow; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Intervention Type: PROCEDURE; Name: O2stand; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: Optiflow; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP
C: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group
D: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nasal High-flow Oxygen Therapy vs Standard Oxygen Therapy Via Venturi Mask in the Post-extubation Period
Brief Summary: The aim of the study is to compare two devices for oxygen therapy, nasal high-flow and Venturi mask, in critically ill patients in the post-extubation period. The hypothesis is that nasal high-flow may be superior to the Venturi mask in terms of oxygenation


Options:
A: Arm Label: High Flow Conditioned Oxygen Therapy; Type: EXPERIMENTAL; Interventions: Device: Optiflow (Fisher&Paykel) | Arm Label: Standard Oxygen Therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal cannulae or controlled oxygen concentration mask | Intervention Type: DEVICE; Name: Optiflow (Fisher&Paykel); Assigned to Arm(s): High Flow Conditioned Oxygen Therapy | Intervention Type: DEVICE; Name: Nasal cannulae or controlled oxygen concentration mask; Assigned to Arm(s): Standard Oxygen Therapy
B: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group
C: Arm Label: Venturi mask; Type: ACTIVE_COMPARATOR; Interventions: Device: Venturi mask | Arm Label: Nasal high-flow; Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal high-flow | Intervention Type: DEVICE; Name: Venturi mask; Assigned to Arm(s): Venturi mask | Intervention Type: DEVICE; Name: Nasal high-flow; Assigned to Arm(s): Nasal high-flow
D: Arm Label: CF patients HFN; Type: EXPERIMENTAL; Interventions: Device: High flow nasal oxygen cannula | Arm Label: CF patients NIV; Type: EXPERIMENTAL; Interventions: Device: Noninvasive ventilation | Intervention Type: DEVICE; Name: High flow nasal oxygen cannula; Assigned to Arm(s): CF patients HFN | Intervention Type: DEVICE; Name: Noninvasive ventilation; Assigned to Arm(s): CF patients NIV

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Brief Summary: The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis


Options:
A: Arm Label: Control, low turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, low turnover; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Cinacalcet | Arm Label: Control, high turnover; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment, high turnover; Type: EXPERIMENTAL; Interventions: Drug: Alendronate | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Treatment, high turnover | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Treatment, low turnover | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Treatment, low turnover
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Denosumab 60 mg Q6M; Type: EXPERIMENTAL; Interventions: Drug: Denosumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Denosumab 60 mg Q6M
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ibandronate [Bonviva/Boniva] | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alendronate | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ibandronate [Bonviva/Boniva]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): 3
D: Arm Label: Romosozumab; Type: EXPERIMENTAL; Interventions: Drug: Romosozumab, Drug: Denosumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Denosumab | Intervention Type: DRUG; Name: Romosozumab; Assigned to Arm(s): Romosozumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Denosumab; Assigned to Arm(s): Placebo, Romosozumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hatha Yoga Exercises in Pelvic and Lumbar Back Pain in Pregnant Woman
Brief Summary: The aim of this study is to identify evaluate the effectiveness of stretching exercises of Hatha Yoga method in pregnant women with back pain and posterior pelvic City Paulínia. -There will be a randomized clinical trial with 60 pregnant women with these symptoms. They will be randomly divided into 2 groups. The group A will perform the exercises of Hatha Yoga for ten weeks, once a week group B postural follow the guidelines recommended for the treatment of these pains, for ten weeks. Will be used as a technique for evaluating the Visual Analogue Scale to measure pain intensity and confirmation tests of the lumbar and posterior pelvic pain in order to differentiate them. A descriptive statistical analysis of univariate and bivariate distributions will be made through frequency and graphical representation. The association between the variables will be tested by statistical tests: \[chi-square (X ²)\], Fisher's exact test, Student's t test or Mann-Whitney, \[Student's t test to compare means\], ANOVA for the analysis of effects between the groups. \[The significance level is predetermined to 5%\]. The data will be analyzed in EPI-INFO 2000. SAS 9.0 and from the database created .


Options:
A: Arm Label: postural orientations; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: hatha yoga | Arm Label: hatha yoga exercises; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: hatha yoga | Intervention Type: BEHAVIORAL; Name: hatha yoga; Assigned to Arm(s): hatha yoga exercises, postural orientations
B: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
D: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Spinal Manipulation; Type: EXPERIMENTAL; Interventions: Procedure: Spinal Manipulation | Arm Label: Neuroemotional technique (NET); Type: EXPERIMENTAL; Interventions: Procedure: Neuroemotional Technique (NET) | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: PROCEDURE; Name: Spinal Manipulation; Assigned to Arm(s): Spinal Manipulation | Intervention Type: PROCEDURE; Name: Neuroemotional Technique (NET); Assigned to Arm(s): Neuroemotional technique (NET)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week, Multinational, Multicentre, Randomised, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of CHF 1535 200/6µg Versus Beclomethasone Dipropionate in Adult Asthmatic Patients Not Adequately Controlled on High Dose of Inhaled Corticosteroids or on Medium Dose of Inhaled Corticosteroids Plus Long-acting β2 Agonists
Brief Summary: The purpose of this study is to show the superiority of CHF 1535 (BDP/FF) pMDI over BDP HFA pMDI in terms of lung function considering change from baseline to the entire treatment period in average pre-dose morning PEF in adult asthmatic patients not adequately controlled on high doses of ICS or on medium dose of ICS+LABA.


Options:
A: Arm Label: Symbicort "as needed"+placebo Pulmicort bid; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol 'as needed' + budesonide placebo bid | Arm Label: terbutaline "as needed"+placebo Pulmicort bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: terbutaline 'as needed' + placebo budesonide bid | Arm Label: Pulmicort bid + terbutaline "as needed"; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide bid + terbutaline 'as needed' | Intervention Type: DRUG; Name: budesonide/formoterol 'as needed' + budesonide placebo bid; Assigned to Arm(s): Symbicort "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: terbutaline 'as needed' + placebo budesonide bid; Assigned to Arm(s): terbutaline "as needed"+placebo Pulmicort bid | Intervention Type: DRUG; Name: budesonide bid + terbutaline 'as needed'; Assigned to Arm(s): Pulmicort bid + terbutaline "as needed"
B: Arm Label: CHF 1535 200/6µg; Type: EXPERIMENTAL; Interventions: Drug: CHF1535 200/6 µg | Arm Label: BDP 100µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: BDP 100 µg | Intervention Type: DRUG; Name: CHF1535 200/6 µg; Assigned to Arm(s): CHF 1535 200/6µg | Intervention Type: DRUG; Name: BDP 100 µg; Assigned to Arm(s): BDP 100µg
C: Arm Label: Symbicort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol (SYMBICORT) pMDI | Arm Label: Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide HFA pMDI | Intervention Type: DRUG; Name: Budesonide/formoterol (SYMBICORT) pMDI; Assigned to Arm(s): Symbicort | Intervention Type: DRUG; Name: Budesonide HFA pMDI; Assigned to Arm(s): Budesonide
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide and placebo | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide and placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Utility of Indomethacin as Support Treatment in Women With Preterm Labor With Intact Membranes and High Risk of Intraamniotic Inflammation
Brief Summary: To demonstrate if indomethacin associated to conventional treatment for preterm labor is useful to delay delivery and to improve neonatal morbimortality in women with preterm labor with high risk of intraamniotic inflammation


Options:
A: Arm Label: group Nicorandil; Type: OTHER; Interventions: Drug: Potassium Channel Opener | Arm Label: group Nifedipine; Type: OTHER; Interventions: Drug: Calcium channel blocker | Intervention Type: DRUG; Name: Potassium Channel Opener; Assigned to Arm(s): group Nicorandil | Intervention Type: DRUG; Name: Calcium channel blocker; Assigned to Arm(s): group Nifedipine
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): indomethacin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Group 1 - Atosiban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atosiban | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Atosiban and nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Group 1 - Atosiban | Intervention Type: DRUG; Name: Atosiban and nifedipine; Assigned to Arm(s): Group 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atosiban | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Generic Protocol for the Collection of Early Pregnancy Urines
Brief Summary: Female volunteers, wishing to become pregnant will be offered the use of Clearblue ovulation prediction products to help identify their most fertile time and aid conception. Volunteers will provide SPD with a daily urine sample throughout the study period, which will be used for the development and validation of SPD products related to pregnancy and fertility.


Options:
A: Arm Label: Electronic hormonal fertility monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic hormonal fertility monitoring | Arm Label: Cervical mucus monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-monitoring | Intervention Type: BEHAVIORAL; Name: Electronic hormonal fertility monitoring; Assigned to Arm(s): Electronic hormonal fertility monitoring | Intervention Type: BEHAVIORAL; Name: Self-monitoring; Assigned to Arm(s): Cervical mucus monitoring
B: N/A
C: Arm Label: sample collection; Type: OTHER; Interventions: Other: Ovulation predictions products | Intervention Type: OTHER; Name: Ovulation predictions products; Assigned to Arm(s): sample collection
D: Arm Label: COTS; Type: ACTIVE_COMPARATOR; Interventions: Device: Clearblue Connected Ovulation Test System | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Clearblue Connected Ovulation Test System; Assigned to Arm(s): COTS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patterned Experience for Preterm Infants
Brief Summary: The PEPI study is designed to provide a patterned feeding experience. By using a regularly occurring and necessary caregiving event, feeding, as the vehicle for the patterned experience, the intervention should be effective at promoting and reinforcing neuronal growth and connections that are critical for neurobehavioral and cognitive function while at the same time being cost effective in its delivery.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention group | Arm Label: Control group; Type: SHAM_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Patterned Experience Group; Type: EXPERIMENTAL; Interventions: Behavioral: Patterned Experience | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patterned Experience; Assigned to Arm(s): Patterned Experience Group
C: Intervention Type: DEVICE; Name: partial-vacuum milk bottle; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: anti-vacuum milk bottle; Assigned to Arm(s): N/A
D: Arm Label: skin to skin contact; Type: EXPERIMENTAL; Interventions: Other: skin to skin contact | Arm Label: Control group; Type: EXPERIMENTAL; Interventions: Other: Control group | Intervention Type: OTHER; Name: skin to skin contact; Assigned to Arm(s): skin to skin contact | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: B